Ann: Appendix 4C - quarterly, page-31

I suspect/hope rather than a buyout we will do a lic deal with a few hundred million and a % of sales on into the future and the company can realise its stated reason for being...

To be a mid-stage biotech company taking really interesting orphaned assets that do not fit their current owners focus and bring them through mid-late stage trials and into partnership for commercialisation.

This is exactly what we are doing with Paxalisib which has become so interesting to the medical science community and what we could be doing with a suite of compounds and building a stable of lic royalties distributed across commercial partnerships.

A distributed source of income streams and a focus to interesting medical science benefiting patients across multiple conditions would be an excellent future for Kazia.